Evandro de Azambuja, BSMO President 2023-2026, shared on LinkedIn:

“Our paper highlighting the prognostic value of residual disease (RD) biology and gene expression after NAT in patients with HER2-positive EBC – intrinsic subtypes at baseline provide more prognostic information while immune gene expression signatures provide more prognostic information in RD.”

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC) – Annals of Oncology

Authors: A. Fernandez-Martinez, M. Tanioka, S.G. Ahn, P. Zagami, T. Pascual, M. Rediti, G. Tang, K.A. Hoadley, D. Venet, N.U. Rashid, P.A. Spears, S. Di Cosimo, E. de Azambuja, A. Choudhury, P. Rastogi, M.N. Islam, J. Cortes, A. Llombart-Cussac, S.M. Swain, C. Sotiriou, A. Prat, C.M. Perou, L.A. Carey

Evandro de Azambuja: The prognostic value of residual disease RD biology and gene expression after NAT in HER2-positive EBC